What’s happening to the GSK share price?

The GSK share price has been under pressure over the past 12 months. This Fool would avoid the company as it continues to struggle.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GSK (LSE: GSK) share price has really struggled over the past year. Shares in the pharmaceutical company have fallen by 18%, excluding dividends.

Over the same time frame, the FTSE 100 has returned around 16%, excluding dividends.

To put it another way, shares in GlaxoSmithKline have underperformed the market by 34%, excluding dividends over the past 12 months. 

Why has the stock performed so poorly, and should I take advantage of this underperformance and acquire some shares in the pharmaceutical giant for my portfolio? 

GSK share price doubts  

It would appear that the market has been giving Glaxo the cold shoulder because of doubts about the company’s growth potential.

While the business has a strong portfolio of treatments already on the market, analysts are expressing concern that the firm is not investing enough for the future. Its product pipeline, they argue, is thin compared to other companies such as AstraZeneca

I think this is a credible argument. If the company is not investing enough for the future, profits are unlikely to grow. That means the GSK share price could continue to tread water. 

Another headwind has been the coronavirus pandemic. During the first quarter, revenues fell 18% as patients delayed their shingles vaccinations (as well as other routine treatments).

This trend is likely to persist for the next few quarters. Unlike Astra, the company has struggled to develop its own coronavirus vaccine. This means it has to sit on the sidelines while its London-listed peer helps vaccinate the world. 

Growth initiatives 

The company is making progress in some areas. For example, it plans to launch a new HIV drug, a new long-acting treatment for severe asthma and there is the demerger of the £30bn Advil to Sensodyne consumer healthcare division. This is planned for the middle of 2022.

Analysts have long argued that Glaxo’s consumer healthcare business could be worth more as an independent operation. But unfortunately at this stage, it seems as if the market remains ambivalent about the potential demerger. 

Overall, I think the company’s outlook is uninspiring. However, I believe the involvement of US hedge fund Elliott Management, which recently acquired a significant stake in the business, could be a catalyst for change. 

Elliot has a reputation for being aggressive and forcing the companies in which it owns stakes to change. The hedge fund’s very involvement has already been a positive catalyst for the GSK share price. The stock has jumped around 5% since the position was revealed. 

The bottom line 

Considering all of the above, I think the outlook for the GSK share price remains mixed.

The way I see it, the stock’s most appealing quality today is its dividend yield. The shares offer a yield of 5.9%, but it is not guaranteed.

Management may have to cut the payout after the demerger or reduce shareholder distributions to free up more cash for research and development.

As such, I would not buy the stock today. I think the company’s dividend yield is on shaky ground, its growth outlook is uninspiring, and there’s no telling how the business will react to Elliott.

I’d rather buy other income stocks with better growth prospects for my portfolio. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »